

We will all learn to live with this illness, Chronic Myelogenous Leukemia, that is in one of us.
I hope to share the journey with others and to make a difference along the way.









And so I find myself relaxed, quiet and peaceful and playing with some of my photographs again. This sunrise really sang to me today and I thought of Nick and Diane and family who are struggling really hard to fight off the effects of cml. I wish them all the peace and the quietness that this picture conjures, and then tons more. 
Jackson Adjunct Professor Shaoguang Li, M.D., Ph.D., who now has a laboratory at the University of Massachusetts Medical School in
In research published in the journal Nature Genetics, the researchers also showed that an asthma medication for human patients is an effective treatment for CML in mice.
The gene, Alox5, processes essential fatty acids to leukotrienes, which are important agents in the inflammatory response. But according to the researchers, Alox5 has a more sinister side. It is vital to the development and maintenance of cancer stem cells.
Cancer stem cells are slow-dividing cells that are thought to give rise to a variety of cancers, including leukemia, and to be critical for maintaining them. Researchers theorize that cancer stem cells must be targeted for effective treatment of many cancers, but direct evidence is still lacking.
The researchers found that CML did not develop in mice without Alox5 because of impaired function of leukemia stem cells. Also, Alox5 deficiency did not affect normal stem cell function, providing the first clear differentiation between normal and cancer stem cells.
Li also treated mice with CML with Zileuton, an asthma medication that inhibits the Alox5 inflammation pathway, as well imatinib, commonly known as Gleevec, the most effective current leukemia medication. Imatinib effectively treated CML, but Zileuton was more effective. The two drugs combined provided an even better therapeutic effect.
The Jackson Laboratory is seeking patent protection on the novel approach to treat CML that Li and colleagues have demonstrated.
The exact mechanism for the Alox5 gene in regulating the function of leukemia stem cells but not normal stem cells needs further study, but it appears that the two types of stem cells employ different pathways for self-renewal and differentiation. The findings provide a new focus of study into how leukemia stem cells are distinct from normal stem cells and how they can be targeted in cancer therapies. A future clinical trial targeting Alox5 will provide the first anti-stem cell strategy in cancer therapy. It is likely that other cancer stem cells will have specific pathways that also differentiate them from their normal stem cell counterparts.
###
Li conducted the research primarily at The Jackson Laboratory, with collaborators at
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in



Chronic myelogenous leukaemia (CML) was long-considered one of the deadliest forms of cancer, capable of striking at any time, causing extreme pain and worse still, affecting both adults and young children. Before the work of two pioneering medical researchers, a diagnosis of CML and subsequent attempts at treatment guaranteed prolonged pain and no certainty of remission. But now with Glivec, a cancer fighting drug with a 98 percent remission rate, CML has lost much of its former bite thanks to American oncologist Brian Druker and Swiss medicinal chemist Jürg Zimmermann.
Inventor(s): Jürg Zimmerman, Brian Druker
Invention: CML Treatment (marketed as Glivec)
Sector: Healthcare
Company: Novartis
In 1960, researchers identified an abnormally short chromosome in 95% of patients with CML, which they named the Philadelphia chromosome. Understanding the phenomenon of the Philadelphia chromosome was seen as the key to curing CML. After another 13 years of research, it was discovered that the Philadelphia chromosome is the result of two chromosomes swapping DNA.
By the early 1980s, researchers demonstrated that the DNA swap resulted in a fusion protein (the product of two genes or proteins joining together) called BCR-ABL. BCR-ABL causes the overproduction of white blood cells in the body. Where healthy blood contains 4,000 to 10,000 white cells per cubic millimetre, blood from a CML patient contains 10 to 25 times this amount.
In 1990, researchers began looking for BCR-ABL inhibitors and at Novartis, a phamaceutical company based in Switzerland, scientist developed a compound designed to reduce BCR-ABL. Jürg Zimmermann and his team set about improving the compound, eventually creating a potent and specific BCR-ABL inhibitor.
In 1994, Novartis teamed with Brian Druker and set about refining and readying the inhibitor for clinical trials that began in 1999. Today, the compound now known as Glivec is being hailed as something of a wonder drug. Follow-up data show that Glivec therapy helped 98% of patients in chronic-phase CML stabilise their blood counts.
Moreover, in 92 percent of cases, the Philadelphia chromosome was completely disabled, though still present. Patients treated with Glivec followed by a bone marrow transplant, a common course of treatment for CML, experienced a cure rate of 60-80%. Side effects of Glivec tend to be mild and easily manageable, with less than 5% of patients experiencing serious adverse effects.
Thanks to the Zimmermann-Druker partnership, the resources at powerhouses like Novartis and the tireless work of other medical researchers, it seems suddenly possible that a cure for cancer may indeed be found in our lifetime.

This is incredible hope! I hold on to it every day even though Steven is doing so very well. I am absolutely thrilled by Dr Druker's dedication to finding a cure for CML. It humbles me tremendously to think that every hour he is thinking about or working on the cure, he is doing this for my kid. I really don't know that there are enough ways to thank this man.
This was an perfect article for me to find and read today, on Mother's Day. Apart from all the flowers, chocolates, cards and phone calls from my three chickens and others - this added that extra light.
I hope all mothers had a wonderful day, felt treasured and loved and appreciated. I certainly did.
love and light,
Annie
Time flies and so many things are going on right now - all good.. but I am only getting to posting Steven's PCR results now - almost a week after they came in! Amazing how time changes things.
So many things swirl through my mind and I wonder sometimes at the wisdom or need to write them down. Many of these thoughts disappear into the days that are screaming past and other keep swirling around the back of my mind.
Two years ago, this little sprite, my youngest grand daughter arrived to brighten our days... and she has done her job really well. She is a pure delight, gorgeous, cute and just plain beautiful too...... Happy Birthday, McKenzie!
